Medicinal agent for treatment of asiderotic anemia

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in prophylaxis and treatment of asiderotic anemia. The preparation comprises components in their following ratio: ferbitol, 80-99%, and gelatin, 1-20%. Invention provides reducing toxicity of the prepared preparation, improvement of its biological activity that results to enhancing therapeutic effectiveness.

EFFECT: enhanced and valuable medicinal properties of agent.

6 ex


The invention relates to medicine and veterinary medicine, namely to pharmacology and therapy, and can be used for the prevention and treatment celesteville anemia.

Iron deficiency anemia was defined as a disease characterized by low content of hemoglobin iron with a subsequent decrease in hemoglobin in the erythrocytes due to iron deficiency due to the mismatch between the intake of iron in the body and its expenditure [1].

For the prevention and treatment of iron deficiency anemia are used medicines containing iron [2].

In medical and veterinary practice iron-containing drugs are used inside and parenteral (mainly intramuscularly or intravenously) [1-3].

The preparations for internal use is represented by ferrous sulfate (activeren, sorbifer durules, conferon, tardyferon, veraplex), chloride (remover, aloe syrup with iron), iron gluconate (poweragent), fumarate iron (ferrata), as well as the preparation of ferric - mellifera [1]. Treatment with oral iron preparations, often salt and divalent effective, simple, cheap, but limited side effects, poor absorbability salt of iron preparations [4].

Preparations for parenteral use presents a comprehensive joint is mi - dextran, dextrin, saharat, gluconate and sorbitol [1, 4, 5]. There is evidence that repeated introduction of iron dextran in the same area of the muscle may contribute to carcinogenesis. In addition, the ion injecting ferrorreporter cause quite serious side effects: pain at the injection site, the taste of iron in his mouth, decreased appetite, fever, urticaria, arthralgia, asthma, nausea and disorders of blood circulation [6]. Gluconate for intravenous iron is so toxic that can only be used in low doses. Iron dextran has a low but significant risk of anaphylaxis [4].

Taking into account the drawbacks of errorreport the search for new drugs for the prevention and treatment of iron deficiency anemia remains relevant.

In General, ferrorreporter for the treatment of iron deficiency anemia presents inorganic salts (sulphates and chlorides), organic compounds (saharat, gluconate, fumarate) and macromolecular complexes - dextran, dextrin. Ferrorreporter made in the form of compounds with lipids and proteins in medical practice are not applied. Proteins can significantly reduce the toxicity of metals, so as to form metalloproteinase complexes, compatible with the tissues of the host and having a substantially m is Nisha annoying activity.

The objective of the invention is to provide iron product for the prevention and treatment of iron deficiency anemia, which combines high biological activity, therapeutic efficacy, low toxicity and good tolerability in comparison with used in medicine and veterinary medicine.

Developed product is an aqueous solution zhelezorudnogo complex and gelatin in the following ratio of components: farbital 80-99%, gelatin 1-20%.

The composition allows to achieve the desired therapeutic and prophylactic effect of parenteral or internal medication.

Farbital is a complex compound of iron with setiathome alcohol sorbitol and is intended for parenteral use in clinical practice [7]. In the developed drug gelatin is introduced into herbicola advanced to increase the biological activity and lower toxicity.

Gelatin is a natural product of animal origin. Compatible with animal tissue and human [8]. In developed medicine gelatin significantly reduces the toxicity of the drug increases its biological activity, such as enhancement of the efficiency of prevention and treatment of iron deficiency anemia.

The elaborately the th drug contains 50 mg of trivalent iron in 1 ml of solution.

The drug is a composition, produced as follows:

Example 1. A portion of gelatin weight of 10 g was placed in the flask, add 100 ml of water, soak for about 30 minutes at room temperature, heated to dissolve under stirring, cooled and mixed with 1000 ml of herbicola. The concentration of iron in the product set by evaporation on a water bath until the desired amount of active substance, i.e. up to 1000 ml of thus Obtained product contains 50 mg of trivalent iron in 1 ml.

Example 2. A portion of gelatin with a weight of 100 g is placed in a flask, add 1000 ml of water, soak for about 30 minutes at room temperature, heated to dissolve under stirring, cooled and mixed with 1000 ml of herbicola. The concentration of iron in the product set by evaporation on a water bath until the desired amount of active substance, i.e. up to 1000 ml of thus Obtained product contains 50 mg of trivalent iron in 1 ml.

Example 3. A portion of gelatin mass of 200 g is placed in a flask, add 1000 ml of water, soak for about 30 minutes at room temperature, heated to dissolve under stirring, cooled and mixed with 1000 ml of herbicola. The concentration of iron in the product ustanavli the Ute by evaporation on a water bath until the desired amount of active substance, that is up to 1000 ml of thus Obtained product contains 50 mg of trivalent iron in 1 ml.

Toxicological studies demonstrate the safety of the drug. When a single subcutaneous, intramuscular and oral administration of the drug to determine LD50(sredneseriynoe dose) is not possible, because the maximum input doses of 25-30 ml/kg of body weight of laboratory animals (which is more than 1875 mg trivalent iron per kg weight of laboratory animals - white mice and rats) the drug did not cause a lethal effect. This greatly exceeds the rate LD50iron sorbitol in its parenteral administration of 50 mg/kg for white mouse [4], and twice LD50for iron dextran in its oral administration of 1000 mg/kg of the white mouse [9].

Pathomorphological study by the end of the experiment revealed no irregularities in the structural organization of the internal organs. The drug toxicity refers to hazard class IV - low hazardous substances (GOST 12.1.007-76). This demonstrates the significant improvement in the safety performance among iron preparations for parenteral use.

Intraperitoneal injection sredneseriynoe dose for rats LDDS ratswas 17,67 ml/kg - that is, 1325 mg Fe/kg LDDS micethe beat is and of 15.5 ml/kg 1163 mg Fe/kg For geisterstreiber complex LDDS rats980 mg/kg (0,98 ml/kg) or 98 mg Fe/kg of body weight [10]. LDDS miceintraperitoneally at a similar zhelezorudnogo drug is 25 mg(Fe)/kg [11], and to declare zhelezorudnogo complex with gelatin - 1163 mg(Fe)/kg, that is, this indicator improved in 46 times.

Examples of use of the product

Example 4. In studies on laboratory animals (white rats), medicines containing 90% zhelezorudnogo complex and 10% gelatin, found that a single subcutaneous (at a dose of 75 mg Fe/kg weight of the animal) the introduction of the drug leads to an increase in the hemoglobin content of 16.9% (148 g/l before administration of the drug to 173 g/l on day 14 after injection). The increase in Hb was 1.78 g/liter in 1 day, it is 75% more in comparison with the increase in Hb with the introduction of the nearest similar product farbital, which amounted to 1,025 g/liter in 1 day [4].

Example 5. After a single intramuscular administration of a medicinal product containing 99% zhelezorudnogo complex and 1% gelatin, in terms of animal farm, the pigs at 3 days of age at a dose of 75-112,5 mg Fe/kg (1,5-2,25 ml per animal), it was found that the drug prevents iron deficiency anemia during the first month of life of the piglets. At approximately adnych data average weight of the pigs head at 60 days of age and the rate of increase in live weight, the application of the proposed drug, than those used for similar purposes by the drug horseferry [12], reduced the incidence of piglets at 65% and improved the safety of 9.7% (reaching safety 100%).

Example 6. For domestic use medicines containing 80% zhelezorudnogo complex and 20% gelatin, pigs ten days of age, patients with iron deficiency anemia, within 10 days at a dose of 5 mg Fe/kg weight of the animal is established that the drug is effective in the treatment of iron deficiency anemia. Baseline hemoglobin level of 12 piglets was 62,00±2.83 g/l and 30 th day of life of the piglets (20-th day of the experiment) he was 120,40±3,29 g/l, color index, respectively 0,84±0.06 and 1,20±0,24. These data are significantly higher than those of the negative control, namely 69,00±1,41 and 92,67±to 6.43, 0,88±0.14 and 0,77±0,04. Thus, the increase in hemoglobin was in the experience of 2.92 g/l and in control of 1.18 g/l, i.e. the indicator is improved by 2.5 times.

The clinical status of the experimental animals in the experiment did not differ from physiological parameters inherent in healthy animals.

The product is stable when stored in a temperature range from 18 to 100°C. Is a homogeneous red-brown liquid, odourless, with low specific taste. The product does not contain free the x iron ions.

Drug containing farbital 80-99%, gelatin 1-20% demonstrates significantly better performance as security - data LD50significantly higher than those of similar - both prophylactic and therapeutic efficacy. The drug can be used parenterally and orally.

Sources of information

1. Sparrows P.A. Anemic syndrome in clinical practice. - M.: Novamed, 2001. - 168 C.

2. Butler LI Iron deficiency anemia. - M.: Novamed, 1998. - 40 S.

3. Karelin A.I. Anemia piglets. - M.: Rosselchozizdat, 1983. - 166 C.

4. The use of intramuscular iron preparations in clinical practice. Chernov V.M. and other Hematology and Transfusiology, 2004, v.49, No.3.

5. Medical and stimulants in non-contagious diseases of animals. Collection of scientific papers. - M., Ed. Uncelebrated, 1981. - S-19.

6. Iron deficiency in children: problems and solutions T.V. Kazakova and other Consilium-Medicum application, 2002, V. 4, No. 3.

7. PPM Mashkovsky. Medicinal product. Ed. 13-E., t.ii. - M.: "Intel Media, 1997. - P.160.

8. State Pharmacopoeia X, St. - M.: Medicine, 1968. - S-334.

9. British Journal of Pharmacology and Chemotherapy. London. UK. v.24, p.352, 1965.

10. American Journal of the Medical Sciences. Slack Inc., Thorofare, NJ, v.241, p.296, 1961.

11. NNAPBA Naunyn-Schmiedebergs Archiv fuer Pharmakologie. (Berlin, Ger.) Volume 270, page R50, 1971.

12. Handbook on import veterina the major drugs. - M.: Kolos, 1998. - 272 S.

Drug for the treatment of iron-deficiency anemia, containing farbital, characterized in that it further contains gelatin in the following ratio, wt.%: farbital 80-99, gelatin 1-20.


Same patents:

FIELD: medicine, pharmacology.

SUBSTANCE: agent for stimulation of erythropoiesis and elimination of iron deficiency comprises hemoglobin obtained from animal blood containing methemoglobin additionally. The ratio of hemoglobin and methemoglobin in the agent = (25-75)-(75-25) wt.-%. The agent shows the expressed heme-stimulating effect. The agent can be used in producing medicinal agents and biologically active supplements.

EFFECT: valuable medicinal properties of agent.

4 dwg

FIELD: medicine, veterinary science, pharmacy.

SUBSTANCE: invention relates to the iron-containing preparation "Ferral". Iron-containing preparation "Ferral" comprises iron in bivalent form - hydroxy-ferrous oxide in the concentration 2-9%. Invention provides administration of the preparation in amount practically by 10 times less as compared with administration of the known preparations that shows the sufficient effect and doesn't cause over dosing.

EFFECT: improved and valuable properties of preparation.

3 tbl, 4 ex

FIELD: medicine, immunology.

SUBSTANCE: invention relates to anemia treatment in infants with immunodeficiency condition. Claimed method includes alternation of tonsilgon H administration in dose of 25 drops 3 times per day for 2 weeks and IRS-19 in one dose in each nasal passage 2 times per day for 2 weeks during 3 months. Course is carried out 2 times per year in spring and autumn for two years on end. In addition to abovementioned preparations 1 ml of tymogen is administered intramuscularly 2 times per week, 2 ml of 12.5 % cycloferon is administered intramuscularly 1 time per week, 2 ml of erytrostim is administered percutaneously 1 time per week during 3 months 2 times per year in spring and autumn for two years on end.

EFFECT: method for effective recovery of red blood shoot and immunodeficiency immunopoesis.

1 tbl, 1 ex

FIELD: medicine, pediatrics, hematology.

SUBSTANCE: the present innovation could be applied in treating surgical and oncological diseases in children during treating and preventing anemia of different etiology. One should introduce ceruloplasmin at daily single dosage ranged 50-200 mg depending upon child's age against 100-200 ml 0.9%-sodiumchloride solution intravenously by drops at the rate of 40-50 drops/min. Moreover, for preventing and/or treating posthemorrhagic anemia in case of surgical operations one should introduce ceruloplasmin during 2 d before surgical operation, intraoperationally, and for 2-10 d after operation. For preventing and/or treating anemia in case of purulent-septic diseases ceruloplasmin should be introduced during chemotherapeutic days during the whole period of the course conducted, for preventing and treating radiation anemia at the background of radiation therapy ceruloplasmin should be injected once weekly during the whole period of radiotherapy course, for preventing and treating toxic and radiation anemia at the background of chemoradiation therapy ceruloplasmin should be introduced once weekly on the day of chemotherapy during the whole course of chemoradiation treatment. The innovation enables to avoid inflows of erythrocytic mass and donor's blood along with shortened number of procedures on introduction of ceruloplasmin and 4-times decrease in the risk for the development of severe anemia in children due to matching peculiar mode for ceruloplasmin introduction.

EFFECT: higher efficiency of therapy and prophylaxis.

4 cl, 5 ex

FIELD: agriculture, animal husbandry, fur farming.

SUBSTANCE: invention relates to preparations used in prophylaxis and treatment of domestic and agricultural animals and for maintaining trace elements composition of fodders. The preparation allows balancing the nutrition diet for animals with the optimal ratio of trace elements providing prophylaxis of many diseases. Proposed preparation comprising complex of iron, manganese, copper, cobalt, selenium and zinc with ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt and water comprises additionally iodine in the following ratio of components: ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt, 15-25; iron (III), 1.5-5.5; manganese (II), 0.25-3.0; copper (II), 0.12-0.55; cobalt (II), from above 0.05 to 0.3; zinc (II), 0.05-1.5; selenium (IV), from above 0.03 to 0.06; iodine (I), 0.01-0.08; water, the balance.

EFFECT: improved and valuable properties of preparation.

1 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: invention proposes an agent for correction of disturbances in production of cytokines and markers of activation of immune system cells in chronic iron-deficient anemia. Agent represents Sorbifer Durules known early as preparation used in treatment of iron-deficient anemia. Invention provides recovering the level of anti-inflammatory cytokines (IL-1, IL-6, IL-8, FNO-α, INF-α and INF-γ) and normalization of cellular immunity by indices of markers CD-25, CD-71 and CD-34.

EFFECT: valuable medicinal properties of agent.

2 tbl, 1 ex

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to method for assay of optimized regimens in dosing erythropoietin (EOR). Invention proposes a system for election of one or some regimens in dosing by using pharmacokinetic/pharmacodynamic (PK/PD) as a model for assay of PK/PD pattern regimens. Then method involves selection of such regimen that provides the serum concentration of EOR exceeding its before administration for 5-30 days between administrations of EOR. Invention provides optimal applying EOR for correction of blood indices changes and treatment of diseases associated with them.

EFFECT: improved and valuable modeling method.

50 cl, 81 dwg, 2 tbl, 8 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: medicine, reconstructive surgery.

SUBSTANCE: the present innovation deals with obtaining osseous plastic material, in particular, to be applied in the field of oral surgery due to carrying out mechanical treatment, degreasing, demineralization, freezing, lyophilization and sterilization. As an allotransplant one should apply the bones of cranial arch. Demineralization should be conducted up to 83-94%, and freezing should be fulfilled in physiological solution at -30 - -35° C for about 24-72 h at 3-5-fold defrosting and change of physiological solution. The innovation enables to obtain an allogenic transplant of decreased antigenic properties and being capable to temporarily substitute the defects of cranial bones of different etiology, sizes and localization followed by development of its own bony tissue of organotopic structure.

EFFECT: higher efficiency.

1 ex

FIELD: medicine, in particular stomatology, traumatology, orthopaedy, and surgical stomatology.

SUBSTANCE: claimed method includes bone tissue cleaning, sawing, defatting, treatment with urea solution, washing, drying, packing and sterilization, wherein after purification bone is sawed to produce slides of 0.1-2.0 cm thickness; treated with 2 % alkali solution washed, treated with 6 M urea solution, then with 3 % hydrogen peroxide; defatted in ethanol and chloroform mixture in ratio of 1:2 (wherein solution is replaced with fresh one not less than 2 times), treated with mixture of 1 % ammonium and 1 % ethanol in ratio of 1:1 (wherein solution is replaced with fresh one not less than 2 times) and saturated with sulfated glycosaminoglycanes up to 800-1500 mug/cm3, dried, packed and sterilized by radiation. Material of present invention is useful in biomaterial preparation, and as carrier for active agents, drugs, cells, as well as in plastic surgery for organ or tissue regeneration.

EFFECT: material containing non-demineralized collagen from bone tissue, sulfated glycosaminoglycanes and water with decreased antigenic characteristic and increased biocompatibility.

2 cl, 1 tbl, 3 ex

FIELD: pharmaceutical technology.

SUBSTANCE: invention relates to technology for processing the natural raw, in particular, velvet antlers of Siberian stags, reinder deer and sika deer to obtain biologically active powder that can be used for preparing cosmetic, pharmaceutical and medicinal preparations and nutrient supplements. Method for preparing the ultradispersed powder from velvet antlers involves cleansing velvet antlers from wool cover, milling the material and its drying, addition of additional grinding bodies, repeated grinding the material in common with additional grinding bodies. As additional grinding bodies method involves biologically active substances with the hardness indices 2.5, not less, by the Mohs hardness scale wherein the initial grinding velvet antlers is carried out to particles size 5 mcm and drying in air flow at temperature 60-70°C, and repeated grinding is carried out to particles size 100 mcm in the sign-variable electrostatic field with the field intensity value 30-32 kW/cm and the ratio of velvet antlers to grinding bodies = 1:(0.2-0.3) followed by carrying out the repeated drying and grinding for 15-30 min wherein blue clays, for example, of Cambrian period and schungite are used as additional grinding bodies. Method provides the simplified technology in manufacturing and high quality in preparing biologically active powder-like product from velvet antlers.

EFFECT: improved preparing method.

3 cl, 1 tbl, 3 ex

FIELD: medicine, traumatology, orthopedics, stomatology, neurosurgery.

SUBSTANCE: invention relates to material designated for replacing defects in different osseous pathologies. Material for replacing osseous tissue defects represents plates consisting of fluorohydroxyapatite in collagen wherein the content of fluorohydroxyapatite is 40-90% by mass. Method for preparing of material involves placing a porous collagen matrix between solutions containing calcium chloride in the concentration 0.2-1 mole/l and solution containing sodium phosphate or ammonium phosphate in the concentration 0.1-1 mole/l and ammonium fluoride in the concentration 0.01-1 mole/l and ammonium or sodium hydroxide solution. Electrophoresis is carried out at current density 7-20 mA/cm2 for 10-24 h, prepared material is washed out with distilled water, dried at 20-37°C and sterilized.

EFFECT: improved preparing method, valuable medicinal properties of material.

3 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves sawing bone into 0.1-2.0 cm thick plates, washing them with 0.1 M phosphate buffer solution having pH equal to 5.8-6.0. The tissue is digested in activated 0.125-0.325% papain at 60°C during 24 h. The plates are washed with 5 water volumes at 60°C and treated at room temperature C during 10-24 h with alkaline solution of 0.4 pH, washed with running water, treated with 3% hydrogen peroxide during 4 h, degreased in mixture of ethanol: chloroform in 1:2 proportion changing solution for a new one not less than twice, decalcified in hydrochloric acid solution of 0.5-1.0 pH, washed with purified water and dried at room temperature, packed and sterilized using radiation.

EFFECT: high collagen quality; low antigen activity.

FIELD: medicine.

SUBSTANCE: method involves placing transplant as 1-5 mm long and 2 mm thick shaving pieces on the bottom and bone walls of pockets filling 1/2 of the volume. The middle part is filled with Hydroxyapol, interdental spaces are filled with suitable shavings fragments modeling interdental partition vertices. Larger thin shaving fragments are subperiosteally introduced. Demineralized bone matrix preserved in 20% urease solution is used as the transplant, Hydroxyapol preparation capsules are used as calcium source. The components are taken in 1:1 proportion.

EFFECT: improved recovery processes; accelerated and simplified surgical operation.

1 tbl

FIELD: medicine, cosmetology.

SUBSTANCE: invention relates to a composition used in the skin care. The composition comprises cartilage extract, grape seeds extract and tomato fruit extract that shows anti-oxidant effect and inhibits formation of free radicals. The composition comprises hydrophilic lipophilic (hydrophobic) antioxidant and cartilage extract that provides the sharp increase of skin collagen synthesis. Proposed composition promotes to reducing collagen activity and levels of final products of progressing glycosylation. Proposed compositions are designated for treatment of ageing skin and for delaying symptoms of the health skin ageing.

EFFECT: improved and valuable properties of compositions.

40 cl, 4 tbl, 4 dwg, 5 ex

FIELD: biotechnology.

SUBSTANCE: claimed method includes utilization of acetic acid as cartilage eluating solvent. According the second embodiment method includes additional filtration of solution containing crude proteoglycan to remove precipitate from said solution. Then filtered solution is centrifuged, ethanol saturated with sodium chloride is added to obtained supernatant, and supernatant is centrifuged to concentrate abovementioned crude proteoglycan in precipitate. According the third embodiment method additionally includes dissolution of said precipitate with acetic acid. Proteoglycan obtained by method of present invention may bi administered perorally.

EFFECT: simplified and environmentally friendly method for proteoglycan production.

3 cl, 3 dwg, 1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves carrying out osteogingivoplasty using alloimplant followed by complex treatment in postoperative period including dimexide solution applications, applying heparin ointment with Trichopol powder or Dicloran gel and using alginate mass as bandage before taking off sutures.

EFFECT: enhanced effectiveness of treatment; reduced risk of complications.

FIELD: medicine, traumatology, orthopedics.

SUBSTANCE: fetal chondrocytes should be introduced at the quantity of 30-100·106 onto the lower surface cartilaginous growth layer. Injection should be performed injectionally after dissecting soft tissues due to osseous tunnelization. The innovation enables to restore defects of articular cartilage, prevents the development and progressing dystrophic processes in articulations with chondral defects due to organotypic restoration of these defects, provides the development of conditions for optimizing reparative processes and increasing adhesion on defect's surface.

EFFECT: higher efficiency.

FIELD: pharmaceutical industry.

SUBSTANCE: claimed complex contains vitamins such as B1, B2, B3 (nicotineamide), B5 (calcium pantothenate), B6, B9 (folic acid), B12, A, C, D3, E, beta-carotene, lycopitin, and minerals such as magnesium, copper, iodine, iron, molybdenum, selenium, calcium, phosphorus, chromium, zinc, and manganese. Complex is separated into two solid formulations taken at different time. The first solid formulations contains B1, B2, B3 (nicotineamide), B5 (calcium pantothenate), B6, B9 (folic acid) and minerals such as magnesium, copper, iodine, iron, molybdenum in specific component ratio; the second one contains A, C, D3, E, beta-carotene, lycopitin, and minerals such as selenium, calcium, phosphorus, chromium, zinc, and manganese in specific component ratio.

EFFECT: vitamin-and-mineral complex of improved antioxidant properties.

6 cl, 1 ex